This review highlights the current state and future perspectives of rational drug design targeting angiotensin II receptors, emphasizing that crystallization of these GPCRs will significantly advance the development of new cardiovascular therapeutics.
No takes yet. Share an insight, caveat, or question.
Rational design advances continue for AT1R/AT2R ligands; leaves open whether receptor crystallization will accelerate new cardiovascular therapies.
Kellici et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: